CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Rating of "Moderate Buy" from Analysts

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $5.02.

Several brokerages recently commented on CTMX. Wedbush reaffirmed an "outperform" rating and issued a $5.00 target price on shares of CytomX Therapeutics in a research report on Friday. HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Prosight Management LP raised its stake in CytomX Therapeutics by 29.2% during the fourth quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company's stock worth $4,022,000 after acquiring an additional 882,891 shares in the last quarter. Millennium Management LLC raised its stake in CytomX Therapeutics by 25.8% during the fourth quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company's stock worth $3,318,000 after acquiring an additional 660,756 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of CytomX Therapeutics in the fourth quarter valued at $2,730,000. Jacobs Levy Equity Management Inc. increased its stake in shares of CytomX Therapeutics by 1.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company's stock valued at $1,594,000 after buying an additional 23,139 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its stake in shares of CytomX Therapeutics by 13.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company's stock valued at $1,422,000 after buying an additional 169,000 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

CytomX Therapeutics Stock Performance

Shares of CTMX traded up $0.05 during mid-day trading on Wednesday, hitting $0.66. The company's stock had a trading volume of 50,153,726 shares, compared to its average volume of 2,603,340. CytomX Therapeutics has a one year low of $0.60 and a one year high of $5.85. The firm has a market capitalization of $52.03 million, a PE ratio of 3.91 and a beta of 1.01. The stock's 50-day moving average is $0.84 and its two-hundred day moving average is $1.02.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.45. The firm had revenue of $38.09 million during the quarter, compared to analysts' expectations of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.